- In April 2023, BioMérieux, a global leader in in-vitro diagnostics, expanded its veterinary diagnostic capabilities by launching an advanced version of its VITEK® 2 Compact system, tailored specifically for veterinary microbiology labs. This system streamlines AST workflows and provides rapid, standardized susceptibility results, helping veterinarians make faster and more informed treatment decisions. The upgrade demonstrates BioMérieux’s commitment to supporting antimicrobial stewardship through automated, reliable, and scalable testing solutions for both companion and food-producing animals
- In March 2023, Thermo Fisher Scientific Inc. announced the development of a next-generation antimicrobial susceptibility testing panel designed for veterinary pathogens. The new panel includes updated breakpoints aligned with global surveillance guidelines, ensuring enhanced diagnostic accuracy. This innovation reflects the company’s proactive approach to combating antimicrobial resistance by providing precise tools that help guide targeted antibiotic therapy in animal health practices
- In March 2023, IDEXX Laboratories, Inc., a prominent player in veterinary diagnostics, launched a cloud-connected platform for AST result reporting. This digital innovation enables seamless sharing of antimicrobial susceptibility results between veterinary clinics and reference labs, improving diagnostic turnaround and data accessibility. The move emphasizes IDEXX’s focus on integrating digital solutions to improve efficiency and antibiotic stewardship in veterinary medicine
- In February 2023, Liofilchem S.r.l., an Italy-based manufacturer of microbiological diagnostic products, introduced its Liofilchem MIC Test Strip (MTS) veterinary range, specifically targeting resistance monitoring in livestock and companion animals. The launch of these easy-to-use strips enhances on-site diagnostic capabilities for veterinarians, offering a reliable alternative for semi-quantitative AST in both clinical and field settings
- In January 2023, Becton, Dickinson and Company (BD) collaborated with a European consortium of veterinary research institutes to pilot an AI-driven AST interpretation tool. This initiative aims to reduce manual interpretation errors and deliver consistent susceptibility readings across veterinary labs. The project highlights the rising influence of AI in veterinary diagnostics and BD’s strategic investment in tools that enhance accuracy, efficiency, and antimicrobial resistance monitoring in the global veterinary space
